Posted by Michael Wonder on 24 Mar 2022
Fresenius Kabi announces FDA approval of SMOFlipid lipid injectable emulsion for paediatric patients requiring parenteral nutrition
24 March 2022 - First and only four-oil lipid injectable emulsion indicated for paediatric parenteral nutrition, including term and preterm neonates.
Fresenius Kabi announced today it has been granted an expanded indication for SMOFlipid lipid injectable emulsion for paediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.
SMOFlipid can be used throughout the continuum of care – from the hospital to home care settings.
